PMID- 34521569
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20220221
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 82
IP  - 11
DP  - 2021 Nov
TI  - Next-generation sequencing and clinical histocompatibility testing.
PG  - 829-837
LID - S0198-8859(21)00208-1 [pii]
LID - 10.1016/j.humimm.2021.08.009 [doi]
AB  - Histocompatibility testing is essential for donor identification and risk 
      assessment in solid organ and hematopoietic stem cell transplant. Additionally, 
      it is useful for identifying donor specific alleles for monitoring donor specific 
      antibodies in post-transplant patients. Next-generation sequence (NGS) based 
      human leukocyte antigen (HLA) typing has improved many aspects of 
      histocompatibility testing in hematopoietic stem cell and solid organ transplant. 
      HLA disease association testing and research has also benefited from the advent 
      of NGS technologies. In this review we discuss the current impact and future 
      applications of NGS typing on clinical histocompatibility testing for transplant 
      and non-transplant purposes.
CI  - Copyright (c) 2021 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Cornaby, Caleb
AU  - Cornaby C
AD  - McLendon Clinical Laboratories, UNC Health, Chapel Hill, NC, USA.
FAU - Schmitz, John L
AU  - Schmitz JL
AD  - McLendon Clinical Laboratories, UNC Health, Chapel Hill, NC, USA; Department of 
      Pathology & Laboratory Medicine, The University of North Carolina at Chapel Hill 
      School of Medicine, Chapel Hill, NC, USA.
FAU - Weimer, Eric T
AU  - Weimer ET
AD  - McLendon Clinical Laboratories, UNC Health, Chapel Hill, NC, USA; Department of 
      Pathology & Laboratory Medicine, The University of North Carolina at Chapel Hill 
      School of Medicine, Chapel Hill, NC, USA. Electronic address: 
      eric_weimer@med.unc.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210911
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Alleles
MH  - Donor Selection/*methods
MH  - Graft Rejection/immunology/prevention & control
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - HLA Antigens/*genetics/immunology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *High-Throughput Nucleotide Sequencing
MH  - Histocompatibility Testing/*methods
MH  - Humans
MH  - Laboratories, Clinical
MH  - Organ Transplantation/adverse effects
MH  - Sequence Analysis, DNA
OTO - NOTNLM
OT  - HLA
OT  - Histocompatibility
OT  - NGS
OT  - Next-generation sequencing
OT  - Transplant
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/09/16 06:00
MHDA- 2022/02/22 06:00
CRDT- 2021/09/15 05:54
PHST- 2021/07/06 00:00 [received]
PHST- 2021/08/12 00:00 [revised]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/09/16 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/09/15 05:54 [entrez]
AID - S0198-8859(21)00208-1 [pii]
AID - 10.1016/j.humimm.2021.08.009 [doi]
PST - ppublish
SO  - Hum Immunol. 2021 Nov;82(11):829-837. doi: 10.1016/j.humimm.2021.08.009. Epub 
      2021 Sep 11.